Melanoma patients under vemurafenib: Prospective follow-up of melanocytic lesions by digital dermoscopy

Journal of Investigative Dermatology

Volumn 134, Issue 5, 2014, Pages 1351-1358

  Perier Muzet, Marie ^a,b   Thomas, Luc ^a,b   Poulalhon, Nicolas ^a   Debarbieux, Sébastien ^a   Bringuier, Pierre Paul ^a,b,c   Duru, Gerard ^b   Depaepe, Lauriane ^a   Balme, Brigitte ^a   Dalle, Stephane ^a,b,c  

^a CENTRE HOSPITALIER LYON SUD   (France)

^b UNIVERSITÉ LYON 1   (France)

^c CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

VEMURAFENIB;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CELL DAMAGE; CLINICAL ARTICLE; DIGITAL IMAGING; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; DYSPLASTIC NEVUS; EPILUMINESCENCE MICROSCOPY; FEMALE; FOLLOW UP; HUMAN; LENTIGO; MALE; MELANOCYTE; MELANOCYTIC LESION; MELANOMA; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; SECOND CANCER; SECOND PRIMARY MELANOMA; TREATMENT DURATION; WILD TYPE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DRUG INDUCED CANCER; FALSE POSITIVE RESULT; MELANOCYTIC NEVUS; METASTATIC MELANOMA; MIDDLE AGED; PRIORITY JOURNAL; SKIN COLOR; SKIN DEFECT; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; DERMOSCOPY; ENZYME INHIBITORS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INDOLES; LENTIGO; LONGITUDINAL STUDIES; MALE; MELANOCYTES; MELANOMA; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; NEVUS, PIGMENTED; PROSPECTIVE STUDIES; SKIN NEOPLASMS; SKIN PIGMENTATION; SULFONAMIDES;

EID: 84900838040     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2013.462     Document Type: Article

References (41)

1. Anforth R, Blumetti TC, Mohd Affandi A et al. (2012) Systemic retinoid therapy for chemoprevention of nonmelanoma skin cancer in a patient treated with vemurafenib. J Clin Oncol 30:e165-7
2. Basile KJ, Abel EV, Aplin AE (2012) Adaptive upregulation of FOXD3 and resistance to PLX4032/4720-induced cell death in mutant B-RAF melanoma cells. Oncogene 31:2471-9
3. Bennani-Lahlou M, Mateus C, Escudier B et al. (2008) [Eruptive nevi associated with sorafenib treatment]. Annales de dermatologie et de venereologie 135:672-4
4. Bower MR, Scoggins CR, Martin RC 2nd et al. (2010) Second primary melanomas: Incidence and outcome. Am Surg 76:675-81
5. Bowling J, Argenziano G, Azenha A et al. (2007) Dermoscopy key points: Recommendations from the international dermoscopy society. Dermatology 214:3-5
6. Boyd KP, Vincent B, Andea A et al. (2012) Nonmalignant cutaneous findings associated with vemurafenib use in patients with metastatic melanoma. J Am Acad Dermatol 67:1375-9
7. Chapman PB, Hauschild A, Robert C et al. (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507-16
8. Chu EY, Wanat KA, Miller CJ et al. (2012) Diverse cutaneous side effects associated with BRAF inhibitor therapy: A clinicopathologic study. J Am Acad Dermatol 67:1265-72
9. Curtin JA, Fridlyand J, Kageshita T et al. (2005) Distinct sets of genetic alterations in melanoma. N Engl J Med 353:2135-47
10. da Rocha Dias S, Salmonson T, van Zwieten-Boot B et al. (2013) The European Medicines Agency review of vemurafenib (Zelboraf(R)) for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma: Summary of the scientific assessment of the Committee for Medicinal Products for Human Use. Eur J Cancer 49:1654-61
11. Dalle S, Poulalhon N, Debarbieux S et al. (2013) Tracking of second primary melanomas in vemurafenib-Treated patients. JAMA Dermatol 149:488-90
12. Dalle S, Poulalhon N, Thomas L (2011) Vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 365:1448-9
13. Davies H, Bignell GR, Cox C et al. (2002) Mutations of the BRAF gene in human cancer. Nature 417:949-54
14. de Giorgi V, Rossari S, Papi F et al. (2012) Risk of second primary melanoma: How should be long follow-up be? Ratio of observed and expected cases. J Eur Acad Dermatol Venereol 26:1454-5
15. Debarbieux S, Dalle S, Depaepe L et al. (2013) Second primary melanomas treated with BRAF blockers: Study by reflectance confocal microscopy. Br J Dermatol 168:1230-5
16. Dummer R, Rinderknecht J, Goldinger SM (2012) Ultraviolet A and photosensitivity during vemurafenib therapy. N Engl J Med 366:480-1
17. Ferrone CR, Ben Porat L, Panageas KS et al. (2005) Clinicopathological features of and risk factors for multiple primary melanomas. JAMA 294:1647-54
18. Gerami P, Sorrell J, Martini M (2012) Dermatoscopic evolution of dysplastic nevi showing high-grade dysplasia in a metastatic melanoma patient on vemurafenib. J Am Acad Dermatol 67:e275-6
19. Gibney GT, Messina JL, Fedorenko IV et al. (2013) Paradoxical oncogenesisthe long-Term effects of BRAF inhibition in melanoma. Nat Rev Clin Oncol 10:390-9
20. Haenssle HA, Kraus SL, Brehmer F et al. (2012) Dynamic changes in nevi of a patient with melanoma treated with vemurafenib: Importance of sequential dermoscopy. Arch Dermatol 148:1183-5
21. Hatzivassiliou G, Song K, Yen I et al. (2010) RAF inhibitors prime wild-Type RAF to activate the MAPK pathway and enhance growth. Nature 464:431-5
22. Huang V, Hepper D, Anadkat M et al. (2012) Cutaneous toxic effects associated with vemurafenib and inhibition of the BRAF pathway. Arch Dermatol 148:628-33
23. Hwa C, Price LS, Belitskaya-Levy I et al. (2012) Single versus multiple primary melanomas: Old questions and new answers. Cancer 118: 4184-92
24. Kim GH, Levy A, Compoginis G (2013) Neutrophilic panniculitis developing after treatment of metastatic melanoma with vemurafenib. J Cutan Pathol 40:667-9
25. Kong HH, Sibaud V, Chanco Turner ML et al. (2008) Sorafenib-induced eruptive melanocytic lesions. Arch Dermatol 144:820-2
26. Lacouture ME, Duvic M, Hauschild A et al. (2013) Analysis of dermatologic events in vemurafenib-Treated patients with melanoma. Oncologist 18:314-22
27. Ma L, Dominguez AR, Collins GR et al. (2012) Hidradenitis suppurativa, eruptive melanocytic nevi, and keratosis pilaris-like eruption in a patient treated with vemurafenib. Arch Dermatol 148:1428-9
28. Menzies SW, Stevenson ML, Altamura D et al. (2011) Variables predicting change in benign melanocytic nevi undergoing short-Term dermoscopic imaging. Arch Dermatol 147:655-9
29. Murali R, Goumas C, Kricker A et al. (2012) Clinicopathologic features of incident and subsequent tumors in patients with multiple primary cutaneous melanomas. Ann Surg Oncol 19:1024-33
30. Nazarian R, Shi H, Wang Q et al. (2010) Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468:973-7
31. [No authors listed] 2011) FDA approves vemurafenib for treatment of metastatic melanoma. Oncology (Williston Park) 25 906
32. Poulikakos PI, Zhang C, Bollag G et al. (2010) RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-Type BRAF. Nature 464:427-30
33. Salerni G, Teran T, Puig S et al. (2013) Meta-Analysis of digital dermoscopy follow-up of melanocytic skin lesions: A study on behalf of the International Dermoscopy Society. J Eur Acad Dermatol Venereol 27:805-14
34. Schmitt L, Schumann T, Inhoff O et al. (2013) Eruptive nevi mimicking wartlike lesions under selective BRAF inhibition in a 37-year-old female melanoma patient. Case Rep Dermatol 5:69-72
35. Sosman JA, Kim KB, Schuchter L et al. (2012) Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 366:707-14
36. Sullivan RJ, Flaherty KT (2013) Resistance to BRAF-Targeted therapy in melanoma. Eur J Cancer 49:1297-304
37. Takata M, Saida T (2006) Genetic alterations in melanocytic tumors. J Dermatol Sci 43:1-10
38. Tromme I, Sacre L, Hammouch F et al. (2012) Availability of digital dermoscopy in daily practice dramatically reduces the number of excised melanocytic lesions: Results from an observational study. Br J Dermatol 167:778-86
39. Villani AP, Zaharia D, Dalle S et al. (2013) Vemurafenib-induced panniculitis. Eur J Dermatol 23:258-60
40. Zimmer L, Hillen U, Livingstone E et al. (2012a) Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. J Clin Oncol 30:2375-83
41. Zimmer L, Livingstone E, Hillen U et al. (2012b) Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management. Arch Dermatol 148:357-61